ThreadThe 2026 US midterm elections

Government · Washington

White House drops FDA nominee Heidi Overton after bipartisan doubts in the Senate

The Trump administration withdrew the nomination of Heidi Overton, a White House health policy aide, a day before a Senate committee was due to vote on her. Republicans and Democrats had both questioned her views on vaccines and abortion.

AI text based on reports by ANSA.it, The Guardian, The New York Times and other publishers. Published . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

Washington · United States
How it came to this
  1. September 2026Overton faces questions at her Senate confirmation hearing
  2. 17 NovWhite House withdraws her nomination on Tuesday night
  3. 18 NovSenate health committee vote had been scheduled for Wednesday morning

The withdrawal

The White House has withdrawn its nomination of Heidi Overton to lead the Food and Drug Administration. A senior administration official told Axios late on Tuesday, 17 November, that she lacked the support in the Senate needed to move forward with confirmation. The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on her nomination on Wednesday, 18 November, but it became clear on Tuesday night that she did not have enough votes. Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated by Donald Trump in August. The agency is therefore still without a permanent commissioner, and the administration must now find a new candidate.

Doubts from both parties

The committee's chairman, Republican Senator Bill Cassidy of Louisiana, had voiced reservations about Overton from the start. He described her role in a summer executive order calling for fewer vaccines recommended for children as "almost disqualifying." On Sunday, Cassidy told CBS's Face the Nation that he could not predict the result of the vote.

“I cannot tell you the outcome of that vote right now.”

Bill Cassidy, republican senator from Louisiana

Democrats focused on abortion. Overton had called the abortion pill mifepristone dangerous to women, and in a 2023 policy brief for the America First Policy Institute she argued that Congress should strictly regulate it. At her hearing she said the drug was safe and effective as labeled under FDA regulations. Republicans on the panel were also uneasy that she gave only vague answers on how she would handle an ongoing safety review of mifepristone at the agency.

The September hearing

At her September confirmation hearing, Overton defended the measles, mumps and rubella vaccine, even though Trump has suggested the shot is deadly. She called the vaccine the best tool available for the measles outbreak.

“It is safe and effective and it is our best tool right now in the public health response to the measles outbreak.”

Heidi Overton, physician and deputy director of the White House Domestic Policy Council

On other subjects she showed loyalty to the president, defending his decisions that career scientists usually make. She skirted questions about how she would keep her political independence at the agency and how she would regulate abortion pills if confirmed.

Kennedy's agenda and the FDA's leadership

A senior administration official said the agency needs a new direction and that the administration fully backs Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda. Kyle Diamantas has served as acting commissioner since Marty Makary resigned in May. Makary's allies have described his exit as a matter of principle, saying he objected to allowing the sale of fruit-flavored vapes. Overton's August nomination had been read as an effort to install a steadier Trump loyalist after a turbulent year at the agency.

Reactions and what comes next

Reproductive Freedom for All, formerly Naral Pro-Choice America, welcomed the decision. Its president and CEO, Mini Timmaraju, said:

“Heidi Overton posed a serious threat to the future of medication abortion access.”

Mini Timmaraju, president and CEO of Reproductive Freedom for All

The Washington Post reported that the administration is unlikely to see an FDA chief confirmed anytime soon. Democrats won sweeping victories in the midterm elections and will control Congress next year.

This article is part of a thread

The 2026 US midterm elections

What changed since this entry:

  1. 18/11White House withdrew Heidi Overton's FDA nomination a day before a Senate committee vote

Ask about this text

Sources and context

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar